Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 104       
ORIGINAL ARTICLE
Year : 2020  |  Volume : 151  |  Issue : 5  |  Page : 444-449

Development of indigenous IgG ELISA for the detection of anti-SARS-CoV-2 IgG


1 Diagnostic Virology Group, ICMR-National Institute of Virology, Pune, Maharashtra, India
2 Maximum Containment Laboratory, ICMR-National Institute of Virology, Pune, Maharashtra, India
3 Human Influenza Group, ICMR-National Institute of Virology, Pune, Maharashtra, India
4 Epidemiology Group, ICMR-National Institute of Virology, Pune, Maharashtra, India
5 Division of Epidemiology & Communicable Diseases, Indian Council of Medical Research, New Delhi, India
6 ICMR-National Institute of Virology, Kerala Unit, Alappuzha, Kerala, India
7 ICMR-National Institute of Virology, Bangalore Unit, Bengaluru, Karnataka, India
8 Department of Microbiology, Kasturba Hospital for Infectious Diseases, Mumbai, Maharashtra, India
9 ICMR-National Institute of Virology, Pune, Maharashtra, India

Correspondence Address:
Pragya D Yadav
Maximum Containment Laboratory, Maximum Containment Facility, ICMR-National Institute of Virology, Sus Road, Pashan, Pune 411 021, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmr.IJMR_2232_20

Rights and Permissions

Background & objectives: Since the beginning of the year 2020, the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacted humankind adversely in almost all spheres of life. The virus belongs to the genus Betacoronavirus of the family Coronaviridae. SARS-CoV-2 causes the disease known as coronavirus disease 2019 (COVID-19) with mild-to-severe respiratory illness. The currently available diagnostic tools for the diagnosis of COVID-19 are mainly based on molecular assays. Real-time reverse transcription-polymerase chain reaction is the only diagnostic method currently recommended by the World Health Organization for COVID-19. With the rapid spread of SARS-CoV-2, it is necessary to utilize other tests, which would determine the burden of the disease as well as the spread of the outbreak. Considering the need for the development of such a screening test, an attempt was made to develop and evaluate an IgG-based ELISA for COVID-19. Methods: A total of 513 blood samples (131 positive, 382 negative for SARS-CoV-2) were collected and tested by microneutralization test (MNT). Antigen stock of SARS-CoV-2 was prepared by propagating the virus in Vero CCL-81 cells. An IgG capture ELISA was developed for serological detection of anti-SARS-CoV-2 IgG in serum samples. The end point cut-off values were determined by using receiver operating characteristic (ROC) curve. Inter-assay variability was determined. Results: The developed ELISA was found to be 92.37 per cent sensitive, 97.9 per cent specific, robust and reproducible. The positive and negative predictive values were 94.44 and 98.14 per cent, respectively. Interpretation & conclusions: This indigenously developed IgG ELISA was found to be sensitive and specific for the detection of anti-SARS-CoV-2 IgG in human serum samples. This assay may be used for determining seroprevalence of SARS-CoV-2 in a population exposed to the virus.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed488    
    Printed283    
    Emailed0    
    PDF Downloaded410    
    Comments [Add]    

Recommend this journal